Our team has extensive experience and qualifications in conducting clinical trials, in particular Phase II and III drug approval studies.

We are currently working as a trial centre in registration studies for the active ingredients dasiglucagon (Zealand Pharma) and RZ358 (Rezolute) 

Dasiglucagon / Zealand Pharma: The recruitment phase for all studies with dasiglucagon has been completed, i.e. no new patients can currently be included.

• The core studies have already been completed: A Randomised Trial in 2 Parts: Double-Blind, Placebo-Controlled, Crossover Part 1 and Open-label Part 2, Evaluating the Efficacy and Safety of Dasiglucagon for the Treatment of Children with Congenital Hyperinsulinism’ (EudraCT 2017-004545-24), as well as “A Two-Period, Open-label Trial Evaluating the Efficacy and Safety of Dasiglucagon for the Treatment of Children with Congenital Hyperinsulinism” (EudraCT 2017-004547-21)
• The ‘long-term extension’ study is expected to end in autumn 2024; recruitment is also not possible here

RZ358 / Rezolute:

• Patients with congenital hyperinsulinism can currently be included in this study under certain conditions - primarily more severe forms that have a persistent tendency to hypoglycaemia under conventional therapy are eligible. If you are interested, please contact us (hi@med.uni-duesseldorf.de), an orientation to the study can be found here on the Homepage of Rezolute Pharma.